Divi’s Laboratories Extends Its Breakout, positive Trend

is showing one of the cleaner continuation structures within the pharmaceutical and contract-manufacturing space. The broader pharma theme remains supported by global outsourcing, supply-chain diversification, rising demand for custom synthesis and renewed interest in high-quality API manufacturers, while Divi’s benefits from scale, execution quality and a strong position in complex manufacturing. On the chart, the most important development is the decisive breakout from the long consolidation zone around ₹6,600–6,800. That resistance had capped price for several months, and once it was cleared, the stock accelerated sharply and has continued making higher highs. Price is now trading near ₹9,315 and remains comfortably above the Ichimoku cloud, with the conversion and base lines also positioned positively. This indicates that both trend and momentum remain in favour of buyers. The recent pause near the highs looks more like consolidation after expansion than immediate distribution. The first area to monitor on any pullback is around ₹9,000, followed by a broader support zone near ₹8,700–8,800. As long as price continues to hold above these levels, the breakout structure remains intact and the trend continues to favour strength over mean reversion.